Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

NCT04493060 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions

BIOLOGICAL: Dostarlimab
DRUG: Niraparib

Sponsor

Mayo Clinic